ClearTrial Draws Global Customer Base to Annual User Group Meeting

ClearTrial Draws Global Customer Base to Annual User Group Meeting
Informative, interactive sessions attended by biopharmaceutical and medical device companies from the US, Europe, and Japan

Chicago, IL - November 4, 2010

ClearTrial, the leading provider of Clinical Trial Operations (CTO) software, announced today that the company held its highly successful Annual User Group meeting in Cambridge, Massachusetts, the heart of the US East Coast biotech industry.  Companies in attendance ranged from small biotech companies to some of the largest biopharmaceutical and medical device companies in the world, including several Top 20 sponsors.  Attendees also encompassed numerous functional areas, including clinical development, clinical operations, outsourcing, finance, business planning and analysis, and project management - reflecting the unique ability of ClearTrial software to optimize clinical studies from "Plan to Payment."

"We're honored to have had such a tremendous turnout for our annual User Group, from companies that are at the forefront of saving lives and making peoples' lives better," noted Andy Grygiel, Vice President of Marketing and Product Management for ClearTrial.  "The User Group meeting was designed to give our customers practical knowledge and guidance to further enhance their ability to meet business objectives using ClearTrial software.  According to the feedback from attendees, the event far exceeded their expectations in doing so."

The ClearTrial Annual User Group meeting featured a blend of presentations, interactive panel discussions, customer case studies, breakout sessions, and advanced training, fostering a free interchange of knowledge and ideas.  Among other sessions, ClearTrial shared its company strategy and long-term product vision with attendees, and provided a sneak preview of ClearTrial v4, the next major release of the award-winning software.

One of the many highlights was a compelling presentation from guest speaker Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development (CSDD).  He presented the results of three Tufts CSDD research projects, including just-completed research that has not yet been published.  Among other summary findings, Getz noted that "the movement to better integrate sponsor-CRO partnerships will help guide efforts to create greater transparency, and more coordinated resource allocation and management."

Following are just a few of the comments from User Group attendees:

"Well done and informative. I am not sure what could have been done better."

"I gained a better understanding of using ClearTrial in specific situations, like extension studies."

"Interaction with my peers and also the ClearTrial staff was very beneficial."


About ClearTrial®

ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, an integrated system for clinical operations planning, forecasting, outsourcing, and project tracking. ClearTrial's award-winning software helps life sciences companies streamline their clinical operations from Plan to PaymentTM without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

 

For more information contact:

Mike Lange
ClearTrial
+1 630.986.9800 x112
[email protected]

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.